CD8A and prostate cancer: These results indicate that both the PTHrP36–44 and PTHrP102–111 peptides have the potential to induce prostate cancer-reactive CTLs from HLA-A24+ prostate cancer patients, and that their cytotoxicity against prostate cancer was dependent on PTHrP peptide-specific CD8+ T cells.